Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 144.86

+0.5%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (726)	5/21/2001 12:59:07 PM
From: Icebrg	Read Replies (1) of 1834

Robbie Stephens Upgrade. robertsonstephens.com Neurocrine Biosciences, Inc. [NASDAQ: NBIX $32.71] Strong Buy Michael King, Biopharmaceuticals "We are upgrading Neurocrine to a Strong Buy rating for the following reasons: (1) the company's transition into a late-stage product story is imminent, (2) the advantages its insomnia drug has over existing drugs continues to become more apparent, (3) though early, the CRF program for depression/anxiety has enormous potential, and (4) the company will enjoy increasing visibility from positive near term drivers, including clinical trial results and pipeline progress," said King. "We arrive at our one-year target price of $61 by applying a 55x multiple and 25% discount rate on our taxed and fully diluted 2005 EPS estimate."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next